Indian animal health company Zenex has strengthened its European footprint by acquiring VievePharm, a Netherlands-based specialist in phytogenic nutrition. The deal provides advanced bolus technology, a GMP+-certified facility, and access to 25 countries.
As the European Union moves to cut veterinary antibiotic sales by 50% under its Farm-to-Fork Strategy by 2030, demand for science-backed natural alternatives in livestock production is rising sharply. Zenex Animal Health, one of the Indian animal health leaders, has strategically positioned itself at the heart of this shift by acquiring a majority stake in VievePharm, a Netherlands-based specialist in phytogenic animal nutrition.
The acquisition brings Zenex a GMP+-certified Dutch manufacturing facility, an established distribution network across more than 25 countries, and advanced bolus delivery technology—a precision format for mineral, vitamin, and udder health supplementation in livestock.
Dr. Arun Atrey, Managing Director and CEO of Zenex Animal Health, commented: “The acquisition of VievePharm is a logical progression of our first-principles approach to animal healthcare, focusing on prevention and sustainable productivity. By combining VievePharm’s advanced bolus technology and European market access with our R&D depth and global distribution, we are positioned to offer holistic, science-backed solutions that address the root causes of animal health challenges.”
“We are excited about the combination with VievePharm, as it strengthens Zenex’s ability to provide science-backed, herbal alternatives to markets that are increasingly favouring natural products. Strategic acquisitions that provide important capability additions, like VievePharm’s bolus technology and European footprint, will continue to be a vital part of the value creation journey at Zenex as we scale our leadership globally,” added Renuka Ramnath, Chairperson of Zenex and Founder, MD & CEO of Multiples.
For VievePharm, the partnership provides access to global markets and expanded R&D resources, enabling the scaling of its “Best of Nature” phytogenic formulations across Europe and beyond.
Arie Boorsma, Founder of VievePharm, noted: “Joining forces with Zenex allows us to scale our ‘Best of Nature’ philosophy to a global stage. Our commitment to sustainable livestock farming and innovation in animal nutrition aligns perfectly with Zenex’s vision. This partnership will provide the resources and reach necessary to deepen our operations in The Netherlands and take our solutions to farmers across Europe and broader international markets.”
STRATEGIC DRIVERS
The company announced that the transaction is underpinned by three key pillars:
1. Strengthening the naturals portfolio: VievePharm’s phytogenic expertise complements Zenex’s herbal and Ayurvedic range, enhanced by its 2023 acquisition of Ayurvet. The combined portfolio positions Zenex to directly benefit from the EU’s antibiotic reduction mandate, providing farmers with proven natural productivity tools.
2. Advanced bolus manufacturing: VievePharm’s Dutch facility holds GMP+, FSA, and Skal certifications, offering specialist delivery technology for precision nutritional supplementation. Zenex plans to deploy this capability to enhance its product offerings across global markets.
3. Western European presence and export growth: While Zenex currently operates across Asia, Africa, and the CIS, VievePharm’s EU distribution network—serving over 60 customers in 25 countries—gives Zenex a platform to introduce its broader therapeutic and nutritional range into Western Europe for the first time.
With this acquisition, Zenex not only strengthens its naturals portfolio but also gains a critical foothold in Western Europe, positioning the company to meet growing regulatory and market demands for sustainable livestock solutions.
Financial details of the deal were not disclosed.
